<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571580</url>
  </required_header>
  <id_info>
    <org_study_id>RECOVERII</org_study_id>
    <nct_id>NCT04571580</nct_id>
  </id_info>
  <brief_title>Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention</brief_title>
  <acronym>RECOVERII</acronym>
  <official_title>Effect of Low-dose Intracoronary Reteplase During Primary Percutaneous Coronary Intervention on Myocardial Infarct Size in Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ge Junbo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE: To determine whether a therapeutic strategy involving low-dose intracoronary&#xD;
      fibrinolytic therapy with reteplase infused after coronary reperfusion will reduce the&#xD;
      myocardial infarction size.&#xD;
&#xD;
      DESIGN, SETTING, AND PARTICIPANTS: 306 patients presenting at 15 hospitals in China within 12&#xD;
      hours of acute ST-segment elevation myocardial infarction (STEMI) due to a&#xD;
      proximal-mid-vessel occlusion of left anterior descending (LAD) coronary artery occlusion&#xD;
      will be randomized in a 1:1:1 dose-ranging trial design. Patients will be followed up to 1&#xD;
      month.&#xD;
&#xD;
      INTERVENTIONS: Participants will be randomly assigned to treatment with placebo (n = 102),&#xD;
      reteplase 9mg (n = 102), or reteplase 18mg (n = 102) by manual infusion over 2 minutes after&#xD;
      reperfusion of the infarct-related coronary artery and before stent implant.&#xD;
&#xD;
      MAIN OUTCOMES AND MEASURES The primary outcomewas the myocardial infarct size (% left&#xD;
      ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI)&#xD;
      conducted from days 2 through 7 after enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial infarct size</measure>
    <time_frame>from days 2 through 7 after enrollment</time_frame>
    <description>Myocardial infarct size (% left ventricular mass) demonstrated by contrast-enhanced cardiac magnetic resonance imaging (MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of microvascular obstruction</measure>
    <time_frame>from days 2 through 7 after enrollment</time_frame>
    <description>The amount of microvascular obstruction (% of left ventricular mass) demonstrated by late gadolinium-enhanced MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution</measure>
    <time_frame>60 minutes after reperfusion</time_frame>
    <description>The percentage ST-segment resolution on an electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CKMB level</measure>
    <time_frame>immediately before reperfusion (0 hours) and then again at 2 hours and at 24 hours</time_frame>
    <description>CKMB area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>1 and 30 days after PCI</time_frame>
    <description>Left ventricular ejection fraction assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse cardiac events (MACE)</measure>
    <time_frame>30 days after PCI</time_frame>
    <description>The composite of cardiac mortality, nonfatal myocardial reinfarction and target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Blush Grade</measure>
    <time_frame>0-1 hour at the end of PCI</time_frame>
    <description>Angiographic measures of reperfusion. The score goes from 0 to 3, with 3 being normal and 0 being absence of myocardial blush</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI corrected frame count</measure>
    <time_frame>0-1 hour at the end of PCI</time_frame>
    <description>Angiographic measures of reperfusion. Thrombolysis in myocardial infarction score with corrected frame count from angiogram to assess myocardial perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI flow grade</measure>
    <time_frame>0-1 hour at the end of PCI</time_frame>
    <description>Angiographic measures of reperfusion. The score goes from 0 to 3, with 3 being normal and 0 being absence of coronary flow</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Acute ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>reteplase 9mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>reteplase 18mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intracoronary infusion with saline</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reteplase Injection</intervention_name>
    <description>low-dose intracoronary fibrinolytic therapy with reteplase 9mg</description>
    <arm_group_label>reteplase 9mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reteplase Injection</intervention_name>
    <description>low-dose intracoronary fibrinolytic therapy with reteplase 18mg</description>
    <arm_group_label>reteplase 18mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute STEMI with persistent ST-segment elevation or recent left bundle-branch block&#xD;
             with a symptom onset to reperfusion time of 12 hours or less.&#xD;
&#xD;
          2. Angiographic criteria included a proximal-mid coronary artery occlusion (TIMI coronary&#xD;
             flow grade 0 or 1) or, impaired coronary flow (TIMI flow grade 2, slow but complete&#xD;
             filling) in the presence of definite angiographic evidence of large thrombus (TIMI&#xD;
             grade â‰¥2) in left anterior descending (LAD) coronary artery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Rescue PCI after thrombolytic therapy.&#xD;
&#xD;
          2. Need for emergency coronary artery bypass grafting.&#xD;
&#xD;
          3. Presence of cardiogenic shock.&#xD;
&#xD;
          4. Life expectancy of &lt; 6 months.&#xD;
&#xD;
          5. Inability to provide informed consent.&#xD;
&#xD;
          6. Contraindications for the use of thrombolysis, including active internal bleeding,&#xD;
             history of intracranial haemorrhage or ischaemic stroke within 6 months, recent major&#xD;
             surgery or trauma, severe uncontrolled hypertension, thrombocytopenia and severe liver&#xD;
             or kidney failure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Huang</last_name>
    <phone>+8613512142875</phone>
    <email>huang.dong@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanji Ma</last_name>
    <phone>+8618818209857</phone>
    <email>ma.yuanji@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Huang, M.D.</last_name>
      <phone>862113512142875</phone>
      <email>huang.dong@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Dong Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ge Junbo</investigator_full_name>
    <investigator_title>Director, Dept. of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

